AI assistant
CHIMERIC THERAPEUTICS LIMITED — Investor Presentation 2021
Mar 16, 2021
64648_rns_2021-03-16_0faa7e56-8eb6-49af-ae61-e3611ce51783.pdf
Investor Presentation
Open in viewerOpens in your device viewer
ASX ANNOUNCEMENT 17 MARCH 2021
==> picture [61 x 90] intentionally omitted <==
CHIMERIC TO PRESENT AT NWR VIRTUAL INVESTOR CONFERENCE
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company focused on bringing the promise of cell therapy to patients with cancer, is pleased to announce it will present at the NWR Virtual Investor Conference on Thursday 18 March 2021.
The Company invites shareholders and investors to see Chimeric Therapeutics Executive Chairman Paul Hopper and COO Jennifer Chow present an update at 9:00am AEDT on 18 March 2021.
Event: NWR Communications Virtual Investor Conference
Presenting: Paul Hopper (Executive Chairman, Chimeric) and Jennifer Chow (COO, Chimeric) Time: Thursday 18 March 2021, 9:00am AEDT
Investors are invited to submit questions prior to the event to: [email protected]
Investors can register online to view the presentation here: https://us02web.zoom.us/webinar/register/WN_ai6XaBqMS8mwZKsG5FdbKA
For more information on the conference click here: https://nwrconference.webflow.io/
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.
ABOUT CHIMERIC THERAPEUTICS
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer.
Chimeric believes that cellular therapies have the potential to cure cancer and that by combining the Company’s expertise in the development and commercialisation of cell therapies with the world’s most innovative scientists and science, Chimeric will be able to bring the promise of cell therapy to life for more patients.
Chimeric Therapeutics is currently in a phase 1 clinical trial for its lead asset, CLTX-CAR T.
CLTX-CAR T is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM), developed by scientists at the City of Hope Medical Centre in California. CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models while CLTX-CAR T cells were not shown to exhibit off-tumor recognition of normal human or murine cells/tissues, supporting a potential optimal safety profile.
Chimeric Therapeutics is now actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.
CHIMERIC THERAPEUTICS LIMITED | 1
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053, AUSTRALIA
CONTACT
Investors
Paul Hopper Executive Chairman P: +61 406 671 515
W: www.chimerictherapeutics.com
Media
Matthew Wright NWR Communications P: +61 451 896 420 E: [email protected]
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053, AUSTRALIA
CHIMERIC THERAPEUTICS LIMITED | 2